Financial Performance - Net profit attributable to shareholders for the first nine months of 2023 was CNY 12,660,076.62, down 56.18% year-on-year[11]. - Operating revenue for the first nine months of 2023 was CNY 169,781,662.69, representing an 18.91% decline compared to the same period in 2022[11]. - The company's basic earnings per share for the first nine months of 2023 was CNY 0.17, down 66.00% from CNY 0.50 in the previous year[11]. - The company's net profit decreased by 56.18% year-on-year, primarily due to weakened overseas market consumption and increased competition leading to price reductions in the market[14]. - Total operating revenue for the first nine months of 2023 was CNY 169,781,662.69, a decrease from CNY 209,370,432.49 in the same period of 2022, representing a decline of approximately 19%[40]. - Net profit for the first nine months of 2023 was CNY 12,660,076.62, compared to CNY 28,892,943.00 in 2022, reflecting a decrease of approximately 56%[41]. - The total comprehensive income attributable to shareholders was ¥12,660,076.62, down from ¥28,892,943.00, a decline of approximately 56.1%[42]. Cash Flow - The net cash flow from operating activities for the first nine months of 2023 was CNY 17,230,872.40, a decrease of 70.73% year-on-year[11]. - Cash flow from operating activities decreased by 70.73% compared to the same period last year, mainly due to reduced operating income and increased prepaid payments[14]. - The net cash flow from operating activities for the first nine months of 2023 was ¥8,864,133.06, a decrease of 85.2% compared to ¥60,028,342.34 in the same period of 2022[51]. - Cash inflow from operating activities totaled ¥206,878,871.97, down 11.5% from ¥233,765,683.74 year-on-year[51]. - Cash outflow from operating activities increased to ¥198,014,738.91, compared to ¥173,737,341.40 in the previous year, marking a rise of 13.9%[51]. Assets and Liabilities - Total assets as of September 30, 2023, were CNY 420,027,274.92, a decrease of 4.64% compared to the end of 2022[11]. - The total liabilities to total assets ratio (consolidated) was 7.53% as of September 30, 2023, compared to 11.40% at the end of 2022[11]. - The company's current liabilities as of September 30, 2023, total CNY 28,877,363.24, down from CNY 47,237,795.01 at the end of 2022[33]. - Total liabilities as of September 30, 2023, were CNY 31,585,766.19, a decrease from CNY 47,311,962.83 at the end of 2022, representing a reduction of about 33%[38]. - Total equity attributable to shareholders was CNY 387,888,413.60 as of September 30, 2023, compared to CNY 389,977,582.80 at the end of 2022, showing a slight decrease[38]. Investments and Income - Investment income for the first nine months of 2023 increased by 2,797.82% year-on-year, attributed to increased investment in financial products[13]. - Other income decreased by 55.75% year-on-year, mainly due to a reduction in government subsidies received[13]. - The company reported a 67.24% increase in asset disposal income, attributed to the sale of non-applicable fixed assets[14]. - The company's investment activities generated a net cash outflow of 39,798,265.70 yuan, a decrease of 13.64% year-on-year, due to increased fixed asset investments[14]. Shareholder Information - The total number of ordinary shares outstanding remained at 75,631,404, with 75% being restricted shares[19]. - Major shareholders include Zhao Zhuojun with 41.22% and Wu Li with 27.43% of the total shares[21]. Operational Developments - The company obtained a new food production license, increasing its product offerings from 3 to 8, enhancing its market competitiveness[27]. - The company’s raw material "Diosmin" passed GMP compliance checks, allowing it to expand its domestic raw material market[27]. - The company is advancing its project for the expansion of Chengdu Okang Pharmaceutical Co., Ltd., currently in the equipment installation and decoration phase[28]. - The company received acceptance for the listing of citrus flavonoid raw materials, marking a significant step in its domestic market strategy[28]. Future Outlook - The company anticipates a better industry development order as some manufacturers exit the market[14]. - The net cash flow from financing activities reflects the company's strategy to manage its capital structure amid market challenges[15].
欧康医药(833230) - 2023 Q3 - 季度财报